Sei Investments Co. Decreases Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Sei Investments Co. cut its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 65.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 141,915 shares of the biotechnology company's stock after selling 268,765 shares during the period. Sei Investments Co. owned approximately 0.09% of Ironwood Pharmaceuticals worth $629,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Pacer Advisors Inc. raised its stake in shares of Ironwood Pharmaceuticals by 4.0% during the 4th quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company's stock valued at $51,967,000 after buying an additional 450,949 shares during the last quarter. State Street Corp lifted its holdings in Ironwood Pharmaceuticals by 7.3% in the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company's stock valued at $40,870,000 after acquiring an additional 677,024 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Ironwood Pharmaceuticals by 4.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company's stock worth $8,786,000 after purchasing an additional 78,969 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Ironwood Pharmaceuticals by 7.2% in the 4th quarter. Bank of New York Mellon Corp now owns 978,135 shares of the biotechnology company's stock worth $4,333,000 after purchasing an additional 65,357 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of Ironwood Pharmaceuticals by 4.0% during the 4th quarter. Principal Financial Group Inc. now owns 765,356 shares of the biotechnology company's stock worth $3,391,000 after purchasing an additional 29,629 shares during the period.

Wall Street Analyst Weigh In

IRWD has been the topic of a number of recent analyst reports. JMP Securities lowered their price target on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating on the stock in a report on Thursday, January 30th. Craig Hallum decreased their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, January 22nd. Finally, StockNews.com upgraded Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, March 29th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $8.60.

Ironwood Pharmaceuticals Trading Down 6.4 %

NASDAQ:IRWD traded down $0.06 during trading hours on Friday, reaching $0.95. 4,596,703 shares of the company were exchanged, compared to its average volume of 2,448,928. The firm has a market cap of $152.99 million, a PE ratio of -31.52 and a beta of 0.30. Ironwood Pharmaceuticals, Inc. has a twelve month low of $0.91 and a twelve month high of $8.45. The stock's 50-day moving average is $1.55 and its 200-day moving average is $3.12.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company had revenue of $90.55 million for the quarter, compared to analyst estimates of $93.85 million. As a group, research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Insider Transactions at Ironwood Pharmaceuticals

In related news, CEO Thomas A. Mccourt sold 139,064 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the transaction, the chief executive officer now directly owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the transaction, the chief marketing officer now owns 554,007 shares of the company's stock, valued at $975,052.32. The trade was a 6.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 192,381 shares of company stock valued at $338,591 over the last 90 days. 12.90% of the stock is currently owned by corporate insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.